Aurobindo Pharma Quarterly Results for Trading Insights
In Mar 2026, Aurobindo Pharma (AUROPHARMA) reported revenue ₹8,869 Cr and net profit ₹921 Cr — revenue +4.1% YoY. View AUROPHARMA price range for the annual high/low range and current price position.
AUROPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Aurobindo Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Analyse Aurobindo Pharma shareholding analysis to track promoter, FII and institutional holdings.
- Revenue of ₹8,869 Cr in Mar 2026 (-5.3% vs Jun 2026, +4.1% vs Mar 2025)
- Net Profit of ₹921 Cr in Mar 2026 (-10.8% vs Jun 2026, +2.0% vs Mar 2025)
- EBITDA of ₹1,766 Cr in Mar 2026 (-14.2% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹15.86 in Mar 2026 (-11.2% vs Jun 2026)
Aurobindo Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AUROPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8,869 | 9,370 | 8,359 | 8,516 | 7,899 | -5.3% | 4.1% |
| Net Profit (₹ Cr) | 921 | 1,032 | 848 | 903 | 824 | - | - |
| EBITDA (₹ Cr) | 1,766 | 2,059 | 1,752 | 1,894 | 1,634 | - | - |
| EPS (₹) | 15.86 | 17.86 | 14.61 | 15.56 | 14.20 | - | - |
| Operating Margin (%) | 19.0% | 20.0% | 20.0% | 21.0% | 20.0% | - | - |
AUROPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Aurobindo Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Aurobindo Pharma share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AUROPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Aurobindo Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores